Skip to main content

Affimed Value Stock - Dividend - Research Selection

Affimed N.V.

ISIN: NL0010872420, WKN: A12BHU

Market price date: 13.07.2021
Market price: 6,86 USD




Affimed N.V. Fundamental data and company key figures of the share

Annual reports in USD
Key figures 22-04-2021
Cash flow
Net operating cash flow -19.400.000
Capital Expenditures -431.000
Free cash flow -19.831.000
Balance sheet
Total Equity 71.993.000
Liabilities & Shareholders equity 175.725.000
Income statement
Net income -41.366.000
Eps (diluted) -0,560
Diluted shares outstanding 83.470.000
Net sales/revenue 28.360.000

Fundamental ratios calculated on: 13-07-2021

Ratios
Key figures 13-07-2021
Cash flow
P/C -28,53
   
P/FC -27,91
Balance sheet
ROI-23,54
ROE40,97
Income statement
P/E-11,84
Div. Yield0,00%
P/B7,69
P/S19,51


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAFMD
Market Capitalization553.406.080,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.affimed.com


Description of the company

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.affimed.com